Methodological Quality and Risk of Bias of Systematic Reviews and Meta-Analyses on Stem Cells for Knee Osteoarthritis: A Cross-Sectional Survey

Aifeng Liu (draifeng@163.com)  
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine  
https://orcid.org/0000-0001-7318-1277

Weijie Yu  
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Jixin Chen  
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Tianci Guo  
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Puyu Niu  
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Huichuan Feng  
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Yizhen Jia  
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Research Article

Keywords: methodological quality, risk of bias, systematic reviews, meta-analysis, stem cells, knee osteoarthritis, cross-sectional survey, AMSTAR 2, ROBIS

Posted Date: December 14th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1143632/v1

License: Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Clinical guidelines need high-quality studies to support clinical decision-making, in which the evidence often was collected from systematic reviews (SRs) and/or meta-analyses (MAs). At present, the methodological quality and risk of bias (RoB) of SRs/MAs on stem cell therapy for the treatment of knee osteoarthritis (KOA) has been poorly investigated. This study aims to strictly evaluate the methodological quality and RoB in SRs/MAs of stem cell therapy for KOA.

Methods: Four electronic databases (PubMed, Embase, Cochrane Library, and Web of Science databases) were searched, from inception to October 5th, 2021. SRs/MAs involving RCTs or cohort studies on stem cell therapy for the treatment of KOA were included. The methodological quality and RoB were assessed using AMSTAR 2 and ROBIS tool respectively.

Results: In total, 22 SRs/MAs were included. According to the results obtained by AMSTAR 2 tool, all SRs/MAs were rated as “Critically low”. Main methodological weaknesses were as follows: eight items accounted for more than 50% of “No”, including Items 2 Protocol registration (81.82%), Item 7 Study exclusion and justification (86.36%) and Item 15 Investigation and discussion of publication bias (63.64%) were critical items. ROBIS-based RoB assessment showed that all the SRs/MAs were rated as “High”.

Conclusions: The overall methodological quality of the SRs/MAs concerning the application of stem cell therapy in treating KOA is “Critically low”, while the RoB is high. It is difficult to provide effective evidence for the formulation of guidelines for KOA treatment. We suggest that the relevant methodological quality assessment should be carried out in the future before the SRs/MAs are used as clinical evidence.

PROSPERO registration number: CRD42021246924

Introduction

Knee osteoarthritis (KOA) is a chronic joint disease with a global prevalence of approximately 3.8% [1, 2]. According to epidemiological statistics, there are about 14 million KOA patients in the United States, and more than half of these patients develop advanced KOA [3]. In China, the prevalence of KOA is 14.6% [4]. KOA has posed significant challenges to global public health [1]. It is related to multiple factors such as obesity, age, metabolic syndrome, and diet [5]. Various treatments have been developed for the treatment of KOA, including weight loss, functional exercise, drug therapy, osteotomy, and joint arthroplasty, however, cartilage injury and loss can not be effectively repaired [6–8].

In recent years, stem cell therapy has been increasingly popular for articular cartilage repair and regeneration, and expected to become a novel treatment for KOA [9–10]. To critically compare the efficacy and safety of stem cell therapy for treating KOA, numerous systematic reviews (SRs) and meta-analyses (MAs) have been published. However, there are no consistent clinical effectiveness conclusions in pain relief, function improvement, and cartilage repair [11–13]. The replicated SRs/MAs and those with
conflicting findings may have severe defects and can not support clinical decision-making [14]. Stem cell therapy is not recommended by the Osteoarthritis Research Society International (OARSI) to treat KOA based on low-quality evidence [15]. Other national guidelines also indicate that the effectiveness of stem cell therapy should be verified by higher-quality studies [8, 16].

In SRs/MAs, the methodological quality often affects the reliability and accuracy of conclusions [17]. At present, only one study uses the AMSTAR tool to evaluate SRs/MAs that contain both RCTs and non-RCTs regarding the application of mesenchymal stem cells (MSCs) therapy in treating KOA [18]. The results show that the existing SRs/MAs lack high methodological quality [18]. In addition, the application of AMSTAR in SRs/MAs that contained non-RCTs is still limited [19]. At present, AMSTAR has been updated to the second edition [20]. As a new tool to evaluate the methodological quality of SRs/MAs, AMSTAR 2 can assess SRs/MAs incorporated into RCTs and/or non-RCTs, and has been applied in obesity [21], osteoarthritis [22], female menopause [23], sleep [24], and other fields. It is found that most SRs/MAs have low methodological quality. At present, no existing study has employed the AMSTAR 2 tool to evaluate the methodological quality of SRs/MAs involving both RCTs and/or non-RCTs regarding the application of stem cell therapy for KOA.

It is necessary to distinguish the term “methodological quality” with “risk of bias (RoB)”. First of all, methodological quality reflects the standardization of the overall research and production process. Different from methodological quality, bias is derived from the study design, implementation, analysis, and report processes, which will affect the final research results [25]. Meanwhile, it is also important to assess the RoB in SRs/MAs.

The present study was conducted to evaluate the methodological quality and RoB in SRs/MAs of stem cell therapy for KOA by the AMSTAR 2 and ROBIS tools [26].

**Methods**

**Inclusion and Exclusion Criteria**

SRs/MAs involving RCTs or cohort studies on stem cell therapy for the treatment of KOA were included. Additionally, the special type of MAs, such as dose-response MAs and network MAs, were also considered for inclusion. At the same time, studies searching only one database and involving contents irrelevant to SRs/MAs or animal experiments were excluded from this work. Besides, duplicate publications, narrative reviews and protocols of SR/MAs were excluded as well.

To be specific, SRs/MAs including the following comparisons were included: (1) any stem cell therapy alone versus no treatment or placebo; (2) any stem cell therapy alone versus other treatment(s) (such as surgery, hyaluronic acid, and platelet-rich plasma); (3) any type of stem cell therapy combined with other treatment(s) (like surgery, hyaluronic acid, and platelet-rich plasma) versus other treatment(s) alone or combined with placebo; and (4) comparison of two or more types of stem cells. No restriction was applied in the type, course and frequency of stem cells.
Literature search

Two reviewers (W.Y. and J.C.) independently searched the PubMed, Embase, Cochrane Library, and Web of Science databases from inception to October 5th, 2021. No restriction was applied to country or language of publication. First of all, the keywords used in the search strategy included “stem cells,” “mesenchymal stem cells,” “mesenchymal stromal cell*,” “osteoarthritis,” “knee osteoarthritis,” “systematic review,” “meta-analysis,” etc. The detailed search strategy was developed for the PubMed database and subsequently adapted for the other databases (Additional file 1). In addition, some international databases of registered SRs such as the International prospective register of systematic reviews (PROSPERO), and reference lists in the eligible studies were also checked to identify any other potentially eligible SRs/MAs. Any disagreement between them was resolved by consulting with a third author (A.L.).

Literature selection

The retrieved studies were imported into the EndNote 20 software, and then two authors (T.G. and P.N.) independently deleted the duplicates and irrelevant studies by checking titles and abstracts. Later, the full-texts of the remaining studies were checked for their eligibility for inclusion. Any disagreement between them was solved by consulting with a third author (A.L.).

Data extraction

One author (H.F.) was responsible for extracting critical data from the included SRs/MAs and imported them into the Excel 2010 software. The extracted data included the first author, number of authors, publication year, country of the first author, journal name and impact factor, searched databases, number of included RCTs, number of recruited participants, registered information, interventions and funding. The data extraction process was checked independently by the second author (Y.J.). Any disagreement was solved by consulting with a third author (A.L.).

Assessment of methodological quality

The methodological quality of the included SRs/MAs was assessed by one author (W.Y.) using AMSTAR 2. AMSTAR 2 is a critical tool used to evaluate the methodological quality of SRs/MAs involving RCTs and/or non-RCTs of healthcare interventions [20]. It consists of 16 items, including 7 critical and 9 non-critical ones. The overall confidence is rated as high, moderate, low, or critically low. In this study, the methodological quality assessment process was checked independently by the second author (J.C.). Any disagreement between them was settled down by the opinion of a third author (A.L.).
Assessment of risk of bias

Two authors (W.Y. and J.C.) independently assessed the RoB among the included SRs/MAs using the ROBIS tool [26]. It covers four domains, namely, (1) study eligibility criteria, (2) identification and selection of studies, (3) data collection and study appraisal, and (4) synthesis and findings. There are 21 signaling questions prepared in these domains, which are answered as Yes, Probably Yes, No, Probably No, or No Information. Later, the RoB for each domain and the overall RoB for all the included SRs/MAs were graded as low, high, or unclear. Any disagreement between them was settled by negotiation with a third author (A.L.).

Statistical analysis

Descriptive analyses of bibliographic characteristics, methodological quality, and RoB were reported as frequencies with percentages or medians with ranges. The assessment results of methodological quality and RoB based on AMSTAR 2 and ROBIS tool were presented in the forms of tables and bar charts.

Results

Study selection

By adopting the described searching strategy, a total of 375 references were identified. After eliminating 161 duplicates, the titles and abstracts of the rest 214 references were screened, among which, 143 were excluded due to irrelevance. The full-texts of the remaining 71 references were screened. Finally, 22 references were included [11-13, 27-45]. The reference inclusion and exclusion process is shown in figure 1 (Flow diagram of study retrieval and selection).

Characteristics of included SRs/MAs

The characteristics of the enrolled SRs/MAs are presented in Table 1. Among the 22 eligible SRs/MAs, 17 were MAs [12, 13, 27-30, 32, 35, 37-45]. The publication year ranged from 2015 to 2021. In terms of the country of the first author, 50% (n=11) of the publications were from China [13, 27-29, 35, 37, 38, 41-44], 18.18% (n=4) from Korea [12, 32, 33, 40], 9.09% (n=2) from US [31, 36], while 4.55% (n=1) from Netherlands [11], Japan [30], Germany [34], India [39] and Singapore [45], respectively. Regarding the study type, 54.55% (n=12) of SRs/MAs only contained RCTs [12, 13, 29, 35-42, 44], while the remaining SRs/MAs involved both RCTs and non-RCTs [11, 27, 28, 30-34, 43, 45]. More details about the characteristics of the enrolled SRs/MAs are displayed in Additional file 2 (Supplementary Table 1. Details of characteristics in included studies).

All the included studies searched the PubMed database, 81.82% searched the Cochrane Library, 77.27% searched Embase, and 27.27% searched Web of Science. A few SRs/MAs searched the Trial Registry
Platforms. For example, only 27.27% (n=6) of SRs/MAs searched the Clinical Trials.gov [11, 27-29, 37, 43]. Meanwhile, four SRs/MAs searched the Chinese databases [27, 29, 35, 44], involving CBM, CNKI and Wanfang Database. (Additional file 3 Supplementary Table 2. Retrieval source data analysis, Supplementary Table 3. The overall of retrieval source data analysis)

Assessment of methodological quality of the included SRs/MAs

Figure 2 (Methodology adherence of each item for included systematic reviews based on AMSTRA 2) summarizes the methodological adherence of each item in AMSTAR 2 for the included studies. The detailed methodological quality assessment results are shown in Additional file 4 (Supplementary Table 4. Methodological quality assessment of systematic reviews by AMSTAR 2).

Item 1. Research questions and inclusion criteria

36.36% (n=8) of the included SRs/MAs presented the PICO description (population, intervention, comparison, and outcome) to clarify the research questions and inclusion criteria. In particular, two SRs/MAs also described the follow-up timeframe [27, 35], while the remaining six only contained PICO description [11, 13, 37-39, 44] (all rated as “Yes”). However, there were still 63.64% (n=14) of the SRs/MAs rated as “No”, among which, 13 failed to specify the intervention of control group [12, 28-30, 32-34, 36, 40-43, 45] and one did not specify the intervention of control group or selected outcomes [31].

Item 2*. Protocol registration (Critical item)

No SRs/MAs were rated as “Yes”. Specifically, 18.18% (n=4) of the enrolled SRs/MAs were rated as “Partial Yes”, including three reporting a protocol and PROSPERO registration number. However, one SR/MA had inconsistent search strategy with protocol [11], while two lacked complete inclusion and exclusion criteria in the protocol, and did not describe the inconsistency between the implementation process and the protocol [12, 40]. Another SR/MA reported that a protocol was developed in advance and followed the PRISMA reporting guidelines, but the protocol was not registered or published [43]. Meanwhile, 81.82% (n=18) of the SRs/MAs were rated as “No”. Among these 18 SRs/MAs, three referred to a protocol [30, 41, 42], of which, two completed the PROSPERO registration [41, 42]. Still, one failed to provide a PROSPERO registration number [42], one was completely inconsistent with the research content [41], and the remaining one did not describe the protocol content [30]. The remaining 15 SRs/MAs did not refer to a protocol. It was impossible to determine the review methods in advance according to the content of the studies.

Item 3. Study designs for inclusion
There were 27.27% (n=6) of the enrolled SRs/MAs reporting the reasons why specific study designs were included [12, 30, 36, 37, 41, 44] (rated as “Yes”). Of them, one included prospective cohort study with long-term follow-up and emphasized that RCTs alone did not provide sufficient evidence [30], one included RCTs to offer reliable evidence due to the controversial conclusion of previous studies [12], one was carried out because a previously unpublished SRs/MAs involved RCTs alone [36], two included the newly published or high-quality RCTs to update clinical evidence [37, 41], and one considered that the overall quality of previous studies was poor and carried out MAs including RCTs to evaluate the clinical efficacy [44]. The remaining 72.73% (n=16) of the SRs/MAs did not explain the reasons why certain study designs were included (rated as “No”).

**Item 4*. Literature search (Critical item)**

None of the enrolled SRs/MAs used a comprehensive literature search strategy that satisfied all the components required. In addition, 68.18% (n=15) of these SRs/MAs searched two or more databases, provided keywords and search strategy, and justified language or retrieval time restrictions, but supplementary retrieval contents (like published reviews, clinical trial registration platform, field experts, gray literature) were not comprehensively searched. Among these SRs/MAs, one did not consult field experts [11], while for the rest 14 SRs/MAs, one did not retrieve gray literature [43], three did not search the reference list of the included studies or gray literature [27, 29, 37], three did not search the clinical trial registration platform or gray literature [13, 33, 41], seven did not retrieve the reference list of the included studies, gray literature, or clinical trial registration platform [30, 32, 34, 38, 40, 42, 45], which met the minimal requirement (rated as “Partial Yes”). However, 31.82% (n=7) of the SRs/MAs failed to meet the minimal requirement (rated as “No”), among which, five did not provide complete search strategies [28, 35, 36, 39, 44], one did not explain the reason for restricting the English language [12], and one did not offer comprehensive search strategy or explain the reason for restricting the English language [31].

**Item 5. Duplicate study selection, literature screen**

68.18% (n=15) of the enrolled SRs/MAs stated that the literature selection process was conducted by two reviewers independently [11-13, 27-30, 32-34, 36-40] (rated as “Yes”). Of them, only one used kappa value [40]. The remaining 31.82% (n=7) of the SRs/MAs did not describe the literature selection process, and it was difficult to judge whether it was independently completed by two reviewers [31, 35, 41-45] (rated as “No”).

**Item 6. Duplicate data extraction**

77.27% (n=17) of the enrolled SRs/MAs stated that the data extraction process was conducted by two reviewers independently [11-13, 28-30, 32-34, 36-41, 43, 44] (rated as “Yes”). Notably, none SRs/MAs provided kappa value to demonstrate that the process involved two reviewers. The remaining 22.73%
(n=5) of the SRs/MAs did not describe the data extraction process, and it was difficult to judge whether it was independently completed by two reviewers [27, 31, 35, 42, 45] (rated as “No”).

**Item 7*. Study exclusion and justification (Critical item)**

Only 13.64% (n=3) of the SRs/MAs provided a list of excluded studies and justified the reasons for exclusions [27, 28, 44] (rated as “Yes”). The remaining 86.36% (n=19) of the SRs/MAs only described the summary reasons of exclusions and did not provide a list of specific exclusion studies [11-13, 29-43, 45] (rated as “No”).

**Item 8. Description of included studies**

There were no clear indicators to distinguish “Partial Yes” and “Yes”. Therefore, we rated all the studies that described PICOs as “Partial Yes” for conservative evaluation. 81.82% (n=18) of the SRs/MAs described the elements of PICOS (rated as “Partial Yes”). The remaining 18.18% (n=4) of the SRs/MAs were rated as “No”. In particular, three did not describe the control measures [32, 33, 45], and one did not describe the control measures and outcomes [34].

**Item 9*. Risk of bias assessment (Critical item)**

45.45% (n=10) of the enrolled SRs/MAs appropriately used the RoB assessment to assess all of the essential biases (rated as “Yes”). In particular, nine only contained RCTs and used the Cochrane RoB tool to assess all the essential biases [12, 13, 35, 37, 39-42, 44], whereas one included both RCTs and non-RCTs (RCTs: the Cochrane RoB tool, non-RCTs: ROBINS-I) [45]. 9.09% (n=2) of the enrolled SRs/MAs assessed part of the essential biases (RCTs: concealed allocation and blinding; non-RCTs: confounding and selection bias), which met the minimal requirement [30, 43] (rated as “Partial Yes”). Among them, one used the Downs and Black scale but did not evaluate the selective reporting bias [30], whereas the other adopted the modified Newcastle–Ottawa scale for non-RCTs and did not evaluate the selective reporting bias [43]. The remaining 45.45% (n=10) of the enrolled SRs/MAs were rated as “No”, including two adopting the Jadad scale for RCTs [29, 38], five not reporting the significant bias results [11, 27, 28, 32, 33], and three not reporting the tool used [31, 34, 36].

**Item 10. Report on the sources of funding for included studies**

There were 95.45% (n=21) of the SRs/MAs that failed to report the funding information of included studies (rated as “No”). Only 4.55% (n=1) of the SRs/MAs reported it by chart [30] (rated as “Yes”).
**Item 11*. Methods for statistical combination (Critical item)**

36.36% (n=8) of the SRs/MAs included RCTs alone, used appropriate effect sizes and statistical analysis models to pool the data, investigated the potential sources of heterogeneity and adjusted for the existing heterogeneity [13, 35, 38-42, 44] (rated as “Yes”). In addition, 40.91% (n=9) of the SRs/MAs were rated as “No”. In particular, six of these SRs/MAs included both RCTs and non-RCTs, but incorrectly combined two different types of studies [27, 28, 30, 32, 43, 45]. Three SRs/MAs only included RCTs, but did not correct the existing heterogeneity [12, 29, 37]. The remaining 22.73% (n=5) of the SRs/MAs were qualitative studies without data combination [11, 31, 33, 34, 36] (rated as “No MAs conducted”).

**Item 12. Assessment of the potential impact of risk of bias on the results**

13.64% (n=3) of the SRs/MAs included both RCTs and/or non-RCTs with different RoB and investigated the potential impact of RoB on MA or other evidence integration [13, 30, 43] (rated as “Yes”). Of them, one conducted meta-regression [30], one carried out subgroup analysis [13], and one performed sensitivity analysis to evaluate the high-quality studies [43]. However, there were 63.64% (n=14) of the SRs/MAs not investigating the impact of existing RoB on the total effect [12, 27-29, 32, 35, 37-42, 44, 45] (rated as “No”), whereas the remaining 22.73% (n=5) of the enrolled SRs/MAs were qualitative studies without data combination [11, 31, 33, 34, 36] (rated as “No MAs conducted”).

**Item 13*. Result interpretation with risk of bias (Critical item)**

68.18% (n=15) of the SRs/MAs included both RCTs and/or non-RCTs with different RoB and investigated the impact of RoB on results [11, 13, 27-32, 34, 35, 39, 42-45] (rated as “Yes”). Among the 15 SRs/MAs, two discussed the RoB resulting from methodological quality [13, 27]; two mentioned the RoB of different study designs [28, 32]; one reported the RoB of outcome measurement, blinding and randomization [29]; one addressed the RoB of outcome measurement, blinding, randomization, allocation concealment and selective reporting [11]; one discussed the RoB of methodological quality and study design [30]; two addressed the risk of selection bias [31, 34]; one discussed the RoB caused by randomization and small sample size [35]; one reported the RoB of outcome measurement and blinding [39]; one discussed the RoB of implementation [42]; one addressed the RoB of outcome measurement and implementation [43]; one discussed the RoB caused by small sample size [44]; and one addressed the RoB of confounding factors [45]. The remaining 31.82% (n=7) of the SRs/MAs did not investigate the impact of RoB on the total effect [12, 33, 36-38, 40, 41] (rated as “No”).

**Item 14. Exploration and explanation of heterogeneity**
There were 81.82% (n=18) of the SRs/MAs investigating the sources of heterogeneity and discussing the potential impact on the conclusions (rated as “Yes”). The rest 18.18% (n=4) of the SRs/MAs were rated as “No” [12, 28, 29, 38], among which, three investigated the source of heterogeneity but did not thoroughly investigate the existing heterogeneity [12, 28, 38], and one did not report the source of heterogeneity [29].

**Item 15*. Investigation and discussion of publication bias (Critical item)**

13.64% (n=3) of the SRs/MAs employed funnel charts or statistics (Egger's test, Begg's test) to investigate the publication bias and discuss the possible publication bias and its potential impact on the results [29, 43, 45] (rated as “Yes”). However, 63.64% (n=14) of the SRs/MAs were rated as “No”, among which, six did not describe the publication bias [27, 32, 35, 38, 42, 44], and eight investigated the publication bias by funnel chart or statistics (Egger's test, Begg's test), but did not discuss the effects on the results [12, 13, 28, 30, 37, 39-41]. The remaining 22.73% (n=5) of the SRs/MAs were qualitative studies without data combination [11, 31, 33, 34, 36] (rated as “No MAs conducted”).

**Item 16. Report of sources of conflict of interest**

There were 45.45% (n=10) of the SRs/MAs rated as “Yes”, including five stating that they did not receive any funding related to the research and described the potential conflicts of interest [13, 34, 39, 43, 44]. The other five provided information on the sources of funding and explained the role of funds in research (like participation in research design, data collection and analysis, article writing) as well as the potential conflicts of interest [11, 12, 29, 33, 40]. The remaining 54.55% (n=12) of the SRs/MAs were rated as “No”. In particular, three of them reported the source of funding but did not describe the role of funds in research or the potential conflicts of interest [27, 28, 37]; two described the funding and potential conflicts of interest, but did not explain the role of funds in research [30, 41]; one stated that it did not receive any research-related funding, but did not describe the potential conflicts of interest [42]; and six did not describe the source of funding [31, 32, 35, 36, 38, 45].

**Rating of each issue and overall confidence**

Methodological adherence of each item is presented in figure 2 (Methodology adherence of each item for included systematic reviews based on AMSTRA 2). Overall confidence is displayed in figure 3 (Methodology adherence of overall confidence for included systematic reviews based on AMSTRA 2). All the SRs/MAs were rated as “Critically low”, among which, eight items rated as “No” accounted for more than 50%, including Items 1, 2, 3, 7, 10, 12, 15, 16. Of them, Items 2, 7, 15 were the critical items.

**Risk of bias for the included SRs/MAs**
The details of ROBIS in assessing the RoB of each SRs/MAs are presented in Table 2. The figure 4 (Risk of bias for included SRs/MAs based on ROBIS) showed the bias judgments in Phase 2 and Phase 3 by ROBIS in the form of percentages, and all SRs/MAs were rated as “High”.

**Phase 2.1 Study eligibility criteria**

Only 4.55% (n=1) of the SRs/MAs were rated as “Low” [11]. However, 63.64% (n=14) of the SRs/MAs were rated as “High”. In particular, 13 SRs/MAs did not describe the intervention measures of the control group [12, 28, 29, 30, 32-34, 36, 40-43, 45], and one did not present the intervention measures of the control group, nor did it report the selected outcomes [31]. The remaining 31.82% (n=7) of the SRs/MAs were rated as “Unclear” because they did not describe whether the protocol was registered in advance [13, 27, 35, 37-39, 44]. It was difficult to judge whether the predetermined inclusion criteria were followed based on the study contents and whether the limitations were appropriate based on the research characteristics.

**Phase 2.2 Identification and selection of studies**

9.09% (n=2) of the SRs/MAs were rated as “Low” [11, 33]. 86.36% (n=19) of the SRs/MAs did not carry out a comprehensive database search, and PubMed, Embase, Cochrane Library, and Web of Science databases were not all searched [12, 13, 27, 29-32, 34-45] (rated as “High”). In addition, eight did not use methods other than database-based literature retrieval [30-32, 34, 35, 40, 42, 45], seven did not meet the inclusion criteria [12, 29, 36, 37, 39, 43, 44], and one had both of the above [38]. The remaining 4.55% (n=1) of the SRs/MAs were rated as “Unclear” because the search strategy was not described, nor was the related information described [28].

For the 22 SRs/MAs, the 42 original studies involved were considered as RCTs [46-87]. After screening the full-texts, 16 did not meet the inclusion criteria. Of them, eight were not RCTs [49-51, 70, 71, 75, 76, 86], including two cohort studies [49, 70], one protocol [75], one case-control study [51], one with insufficient data [50], one conference abstract [71], one commentary [76], and one with abstract only [86]. Another three RCTs did not focus on patients with KOA [59, 60, 68], with two enrolling patients with cartilage defects of the knee joint [59, 60], and one including patients after anterior cruciate ligament reconstruction [68]. The intervention measures of two RCTs were bone marrow aspirate concentrate (BMAC) [67, 83], and those of three RCTs were Stromal vascular fraction (SVF) [79, 85, 87].

**Phase 2.3 Data collection and study appraisal**

There were 50.00% (n=11) of the SRs/MAs rated as “High”, among which, one did not describe the basic characteristics of the included studies in detail [45], seven did not use appropriate tools to evaluate the RoB [11, 27-29, 31, 36, 38], and three had both of the above two issues [32-34]. The remaining 50.00% (n=11) of the SRs/MAs were rated as “Unclear”, since it was difficult to judge whether all the relevant
research results were extracted for data synthesis, and five of them did not describe the process of RoB assessment. It was also not easy to judge whether the two reviewers completed the RoB assessment process independently [35, 37, 42-44].

**Phase 2.4 Synthesis and findings**

There were 81.82% (n=18) of the SRs/MAs rated as “High”, of which, four with different types of studies were combined and analyzed [30, 34, 36, 43], eight did not deal with RoB in data synthesis [29, 35, 38-42, 44], and six had both of the above two issues [12, 27, 28, 32, 37, 45]. In addition, three SRs/MAs did not deal with the heterogeneity between studies [12, 29, 37]. The remaining 18.18% (n=4) of the SRs/MAs were rated as “Unclear” [11, 13, 31, 33].

**Discussion**

It is the first time that AMSTAR 2 and ROBIS tools have been used to assess the methodological quality and RoB of SRs/MAs in the field of stem cell therapy for KOA. This study included 22 SRs/MAs from eight countries published before October 5th, 2021.

Our results showed that the overall methodological quality of the enrolled SRs/MAs was disappointing. According to the results obtained by AMSTAR 2 tool, all SRs/MAs were rated as “Critically low” [11–13, 27–45]. ROBIS-based RoB assessment showed that all the SRs/MAs were rated as “High”. Besides, eight items accounted for more than 50% of “No”, including Items 1, 2, 3, 7, 10, 12, 15 and 16. Of them, Item 2 Protocol registration, Item 7 Study exclusion and justification and Item 15 Investigation and discussion of publication bias were critical items.

Based on our analysis, following the PRISMA reporting guideline did not seem to improve the methodological quality of the studies. Of the 22 studies, 18 adopted the PRISMA guideline, but all of them were rated as “Critically low”, similar to the conclusion drawn by Xu et al [24]. It may be because that the PRISMA reporting specification only provides researchers with a list of reports to be reported. Still, the final report content and level of detail are up to the researchers. According to the AMSTAR 2, deficiencies of critical items of this study mainly came from Items 2, 7 and 15. The PRISMA reporting guideline reported these items in Items 16b, 21, and 24 [88]. This indicated that most of the SRs/MAs only emphasized the use of the PRISMA reporting guideline but did not fully follow the implementation of the standard, which also resulted in the low methodological quality of the SRs/MAs.

The findings of this work were consistent with the conclusions drawn in other studies. Wu et al. [22] evaluated SRs/MAs in the field of osteoarthritis treatment and found 167 SRs/MAs. Only seven of these studies were rated as high-quality, and 76% of them were rated as “Critically low”. Additionally, the main methodological issues were Items 2, 4, and 7 in AMSTAR 2. Storman et al. [21] discovered that 99% of the SRs/MAs in the field of bariatrics were rated as “Critical low”, and only 6% of the SRs/MAs were rated as low RoB by ROBIS. Yan et al. [89] evaluated SRs/MAs related to robotic surgery and found that 95.1% of
the studies were rated as "Critical low". Typically, Item 2 Protocol registration and Item 10 Report on the sources of funding for included studies were the main methodological issues in AMSTAR 2. Siemens et al. [90] discovered in advanced cancer patients that 88.1% of the SRs/MAs were rated as "Critical low", and the main causes were not providing the list of excluded literature and the reasons for exclusion (83.5%) and not being registered in advance (85.1%). In addition, the AMSTAR 2 tool has been adopted in numerous fields like sleep [24], hip-related pain [91], minimally invasive glaucoma surgery [92], and proton pump inhibitor safety [93] to evaluate the methodological quality of studies.

Noteworthily, the list and reasons for excluded literature and the registration of protocols in advance have significant impacts on the methodological quality of the SRs/MAs. The former should comply with the PRISMA reporting guideline detailedly and cautiously when conducting SRs/MAs. Meanwhile, it is still controversial about whether the latter should be regarded as a critical item of AMSTAR 2. Xu et al. [24] did not take protocol registration as an essential item to evaluate the methodological quality of SRs/MAs in the field of sleep, and thought that it did not reflect the level of methodological quality. Siemens et al. [90] found no significant correlation between protocol registration and methodological quality.

On the contrary, Ge et al. [94] stated that early registration improved the overall methodological quality of SRs/MAs, but the impact on the overall reporting quality was not significant. Sideri et al. [95] found in the field of orthodontics that, the AMSTAR score of the SRs/MAs registered on PROSPERO increased by an average of 6.6%. The registered SRs/MAs had higher methodological quality, regardless of their minor number. In this study, SRs/MAs that registered the protocol in advance or published the research plan were also rated as "Critical low". However, the correlation between protocol registration and methodological quality should be further evaluated in more fields.

Comprehensive literature retrieval is crucial for the comprehensiveness of the SRs/MAs. According to the AMSTAR 2 and PRISMA reporting guidelines, literature retrieval based on electronic databases alone (e.g., PubMed, Embase, Cochrane Library, and Web of science) is not comprehensive. Instead, it is also necessary to search the published reviews, clinical trial registration platforms, gray literature, and consult field experts to reduce the publication bias. Generally speaking, journals are more likely to publish positive results, while studies with negative results are often difficult to be published [96]. In this study, none of the enrolled SRs/MAs adopted a comprehensive literature search strategy. For gray literature retrieval, only 4.55% (n=1) of the SRs/MAs searched the gray literature database [11], and 27.27% (n=6) searched the clinical trial registration platform [11, 27–29, 37, 43]. Winters et al. [97] proposed three methods to control the publication bias, namely, (1) registering before the start of the trial, (2) using a funnel chart to evaluate the publication bias intuitively, and (3) using a comprehensive retrieval strategy to retrieve multiple gray literature data. Unpublished studies may significantly change the clinical effect of SRs/MAs, and more comprehensive literature retrieval strategies should be developed in the future.

The AMSTAR 2 and ROBIS tools have been used in combination in diverse fields such as chronic heart failure [98], dyslipidemia [99], infertility [100], and psoriasis [101]. It has been confirmed that there is a strong correlation between the use of AMSTAR 2 and ROBIS tools for evaluation and the methodological
However, the evaluation items in ROBIS need to be further improved to enhance the consistency of evaluation results among different reviewers [104]. The difference in evaluation between two reviewers may be because that AMSTAR 2 is more specific than the ROBIS evaluation criteria. Further research is warranted to verify the reliability and applicability of these two tools in combination [105].

According to the field of “identification and selection of studies” in ROBIS, 86.36% (n=19) of the SRs/MAs were rated as “high bias risk”, which was mainly ascribed to the inclusion of original studies that did not meet the inclusion criteria. Notably, 42 initial studies involved in the 22 SRs/MAs were considered to be RCTs. After screening the full-texts, 16 did not meet the inclusion requirements. Moreover, nine SRs/MAs included studies that did not meet the inclusion criteria, which accounted for the reason why they had a high RoB in ROBIS [12, 13, 29, 36–39, 43, 45]. In addition, appropriate RoB assessment tools are also necessary to ensure the methodological quality. In this study, 59.09% (n=13) of the SRs/MAs used the Cochrane RoB tool [11–13, 33, 35, 37, 39–45], while 13.64% (n=3) adopted the Jadad scale [28, 29, 38], however, it was unable to evaluate the bias caused by the non-real random distribution and selective reports.

In this study, the AMSTAR 2 tool was employed to evaluate the methodological quality of the SRs/MAs, which was rated as “Critically low” when there were two or more issues in the critical items. In fact, the number of problems in essential issues is also significant to the research quality, and qualitative evaluation is often difficult to reflect their differences objectively. The scoring scheme recommended by the traditional AMSTAR 2 may not be suitable for SRs/MAs with “Critically low” methodological quality.

This study comprehensively evaluated SRs/MAs regarding the application of stem cell therapy in KOA treatment, and almost all the published SRs/MAs in the field of stem cell therapy for KOA were included. Therefore, our results were representative. Nonetheless, certain limitations should be noted. In this study, the gray database was not selected for retrieval, which might cause certain publication bias. In addition, this study focused on evaluating the methodological quality of SRs/MAs, but did not discuss the heterogeneity of SRs/MAs, which might not be addressed or derived from clinical heterogeneity, methodological heterogeneity, or clinical combined with methodological heterogeneity.

**Conclusions**

In conclusion, the overall methodological quality of the SRs/MAs concerning the application of stem cell therapy in treating KOA evaluated by AMSTAR 2 is “Critically low”, while the RoB is high in ROBIS. It is difficult to provide effective evidence for the formulation of guidelines for KOA treatment. We suggest that the relevant methodological quality assessment should be carried out in the future before the SRs/MAs are used as clinical evidence. We should also follow the AMSTAR 2 to carry out related SRs/MAs research in the future, so as to improve the methodological quality.

**Abbreviations**
BMAC
Bone marrow aspirate concentrate
KOA
Knee osteoarthritis
MAs
Meta-analyses
MSCs
Mesenchymal stem cells
OARSI
Osteoarthritis Research Society International
RCTs
Randomized clinical trials
RoB
Risk of bias
SRs
Systematic reviews
SVF
Stromal vascular fraction

Declarations

Supplementary information

Registration and protocol: This study has been registered in PROSPERO (No. CRD42021246924).

Acknowledgements

Not applicable.

Authors’ contributions

A.L. and W.Y. designed the study. W.Y. and J.C. did the literature search, assessment of methodological quality and risk of bias. T.G. and P.N. did the literature selection, H.F. and Y.J. extracted the information and data from the included studies. A.L. and W.Y. did the data analysis and produced the figures and tables. A.L. and W.Y. wrote the paper. A.L. revised the manuscript; A.L. and W.Y. contributed equally to this work. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by a grant from the National Natural Science Foundation of China (81873316). The funding sources were not involved in the study design, collection, analysis or interpretation of the data, writing of the manuscript, or in the decision to submit the manuscript for publication.

Availability of data and materials
The data supporting the conclusions of this study are all online.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

All authors declare that they have no conflict of interest.

References

1. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745-1759.

2. Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323-1330.

3. Deshpande BR, Katz JN, Solomon DH, et al. Number of Persons With Symptomatic Knee Osteoarthritis in the US: Impact of Race and Ethnicity, Age, Sex, and Obesity. Arthritis Care Res (Hoboken). 2016;68(12):1743-1750.

4. Li D, Li S, Chen Q, et al. The Prevalence of Symptomatic Knee Osteoarthritis in Relation to Age, Sex, Area, Region, and Body Mass Index in China: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2020;7:304.

5. Berenbaum F, Wallace IJ, Lieberman DE, et al. Modern-day environmental factors in the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2018;14(11):674-681.

6. Roos EM, Arden NK. Strategies for the prevention of knee osteoarthritis. Nat Rev Rheumatol. 2016;12(2):92-101.

7. Gallagher B, Tjoumakaris FP, Harwood MI, et al. Chondroprotection and the prevention of osteoarthritis progression of the knee: a systematic review of treatment agents. Am J Sports Med. 2015;43(3):734-744.

8. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72(2):220-233.

9. Jiang S, Tian G, Li X, et al. Research Progress on Stem Cell Therapies for Articular Cartilage Regeneration. Stem Cells Int. 2021;2021:8882505.

10. Anderson JA, Little D, Toth AP, et al. Stem cell therapies for knee cartilage repair: the current status of preclinical and clinical studies. Am J Sports Med. 2014;42(9):2253-2261.
11. Pas HI, Winters M, Haisma HJ, et al. Stem cell injections in knee osteoarthritis: a systematic review of the literature. Br J Sports Med. 2017;51(15):1125-1133.

12. Kim SH, Ha CW, Park YB, et al. Intra-articular injection of mesenchymal stem cells for clinical outcomes and cartilage repair in osteoarthritis of the knee: a meta-analysis of randomized controlled trials. Arch Orthop Trauma Surg. 2019;139(7):971-980.

13. Dai W, Leng X, Wang J, et al. Intra-Articular Mesenchymal Stromal Cell Injections Are No Different From Placebo in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Arthroscopy. 2021;37(1):340-358.

14. Ioannidis JP. The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses. Milbank Q. 2016;94(3):485-514.

15. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-1589.

16. Ariani A, Manara M, Fioravanti A, et al. The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of knee, hip and hand osteoarthritis. Reumatismo. 2019;71(S1):5-21.

17. Mulrow CD. Rationale for systematic reviews. BMJ. 1994;309(6954):597-599.

18. Xing D, Wang Q, Yang Z, et al. Mesenchymal stem cells injections for knee osteoarthritis: a systematic overview. Rheumatol Int. 2018;38(8):1399-1411.

19. Pieper D, Buechter RB, Li L, et al. Systematic review found AMSTAR, but not R(revised)-AMSTAR, to have good measurement properties. J Clin Epidemiol. 2015;68(5):574-583.

20. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.

21. Storman M, Storman D, Jasinska KW, et al. The quality of systematic reviews/meta-analyses published in the field of bariatrics: A cross-sectional systematic survey using AMSTAR 2 and ROBIS. Obes Rev. 2020;21(5):e12994.

22. Wu IX, Wang H, Zhu L, et al. Methodological quality of systematic reviews on interventions for osteoarthritis: a cross-sectional study. Ther Adv Musculoskelet Dis. 2020;12:1759720X20959967.

23. Zhang GQ, Chen JL, Luo Y, et al. Menopausal hormone therapy and women's health: An umbrella review. PLoS Med. 2021;18(8):e1003731.

24. Xu C, Furuya-Kanamori L, Kwong JSW, et al. Methodological issues of systematic reviews and meta-analyses in the field of sleep medicine: A meta-epidemiological study. Sleep Med Rev. 2021;57:101434.

25. Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142.
26. Whiting P, Savović J, Higgins JP, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225-234.

27. Xia P, Wang X, Lin Q, et al. Efficacy of mesenchymal stem cells injection for the management of knee osteoarthritis: a systematic review and meta-analysis. Int Orthop. 2015;39(12):2363-2372.

28. Cui GH, Wang YY, Li CJ, et al. Efficacy of mesenchymal stem cells in treating patients with osteoarthritis of the knee: A meta-analysis. Exp Ther Med. 2016;12(5):3390-3400.

29. Yubo M, Yanyan L, Li L, et al. Clinical efficacy and safety of mesenchymal stem cell transplantation for osteoarthritis treatment: A meta-analysis. PLoS One. 2017;12(4):e0175449.

30. Iijima H, Isho T, Kuroki H, et al. Effectiveness of mesenchymal stem cells for treating patients with knee osteoarthritis: a meta-analysis toward the establishment of effective regenerative rehabilitation. NPJ Regen Med. 2018;3:15.

31. Davidson PA, Bland DS, Henderson M. A systematic review of the treatment of knee osteoarthritis with intraarticular injection of mesenchymal stem cells. Current Orthopaedic Practice 2018;29(6):590-596.

32. Shin YS, Yoon JR, Kim HS, et al. Intra-Articular Injection of Bone Marrow-Derived Mesenchymal Stem Cells Leading to Better Clinical Outcomes without Difference in MRI Outcomes from Baseline in Patients with Knee Osteoarthritis. Knee Surg Relat Res. 2018;30(3):206-214.

33. Ha CW, Park YB, Kim SH, et al. Intra-articular Mesenchymal Stem Cells in Osteoarthritis of the Knee: A Systematic Review of Clinical Outcomes and Evidence of Cartilage Repair. Arthroscopy. 2019;35(1):277-288.e2.

34. Migliorini F, Rath B, Colarossi G, et al. Improved outcomes after mesenchymal stem cells injections for knee osteoarthritis: results at 12-months follow-up: a systematic review of the literature. Arch Orthop Trauma Surg. 2020;140(7):853-868.

35. Wang R, Zhao L, Huang C. Clinical efficacy and cartilage repair effect of mesenchymal stem cells intra-articular injection for knee osteoarthritis: a meta-analysis of randomized control trials. Chinese Journal of Rheumatology. 2019;23(12):803-809.

36. Hall M, McCafferty J, Agarwalla A, et al. Safety and Efficacy of Cultured/Noncultured Mesenchymal Stromal Cells without Concurrent Surgery for Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials. J Long Term Eff Med Implants. 2020;30(1):31-47.

37. Han X, Yang B, Zou F, et al. Clinical therapeutic efficacy of mesenchymal stem cells derived from adipose or bone marrow for knee osteoarthritis: a meta-analysis of randomized controlled trials. J Comp Eff Res. 2020;9(5):361-374.

38. Huang R, Li W, Zhao Y, et al. Clinical efficacy and safety of stem cell therapy for knee osteoarthritis: A meta-analysis. Medicine (Baltimore). 2020;99(11):e19434.

39. Jeyaraman M, Muthu S, Ganie PA. Does the Source of Mesenchymal Stem Cell Have an Effect in the Management of Osteoarthritis of the Knee? Meta-Analysis of Randomized Controlled Trials. Cartilage. 2020:1947603520951623.
40. Kim SH, Djaja YP, Park YB, et al. Intra-articular Injection of Culture-Expanded Mesenchymal Stem Cells Without Adjuvant Surgery in Knee Osteoarthritis: A Systematic Review and Meta-analysis. Am J Sports Med. 2020;48(11):2839-2849.

41. Ma W, Liu C, Wang S, et al. Efficacy and safety of intra-articular injection of mesenchymal stem cells in the treatment of knee osteoarthritis: A systematic review and meta-analysis. Medicine (Baltimore). 2020;99(49):e23343.

42. Wang J, Zhou L, Zhang Y, et al. Mesenchymal stem cells - a promising strategy for treating knee osteoarthritis. Bone Joint Res. 2020;9(10):719-728.

43. Song Y, Zhang J, Xu H, et al. Mesenchymal stem cells in knee osteoarthritis treatment: A systematic review and meta-analysis. J Orthop Translat. 2020; 24:121-130.

44. Qu H, Sun S. Efficacy of mesenchymal stromal cells for the treatment of knee osteoarthritis: a meta-analysis of randomized controlled trials. J Orthop Surg Res. 2021;16(1):11.

45. Tan SHS, Kwan YT, Neo WJ, et al. Intra-articular Injections of Mesenchymal Stem Cells Without Adjuvant Therapies for Knee Osteoarthritis: A Systematic Review and Meta-analysis. Am J Sports Med. 2021:363546520981704.

46. Wakitani S, Imoto K, Yamamoto T, et al. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage. 2002;10(3):199-206.

47. Xu Yougao, Hu Juzheng, Wang Yong, et al. Comparative study of bone marrow mesenchymal stem cells transplantation in the treatment of knee osteoarthritis. Chinese Journal of New Clinical Medicine. 2009;1250-1252.

48. Varma HS, Dadarya B, Vidyarthi A. The new avenues in the management of osteo-arthritis of knee-stem cells. J Indian Med Assoc. 2010;108(9):583-585.

49. Nejadnik H, Hui JH, Feng Choong EP, et al. Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study. Am J Sports Med. 2010;38(6):1110-1116.

50. Bhattacharya N. Clinical use of amniotic fluid in osteoarthritis: a source of cell therapy. Transplantation. 2011; 90:395–403.

51. Koh YG, Choi YJ. Infrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis. Knee. 2012;19(6):902-907.

52. Wong KL, Lee KB, Tai BC, et al. Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years’ follow-up. Arthroscopy. 2013;29(12):2020-2028.

53. Tan Y, Jiang M, Y H, et al. Therapeutic effect of arthroscopy combined with autologous bone marrow stem cell grafting on knee osteoarthritis. J Tradit Chin Orthop Traumatol. 2013;10:35–38.

54. Saw KY, Anz A, Siew-Yoke Jee C, et al. Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial. Arthroscopy. 2013;29(4):684-694.
55. Koh YG, Kwon OR, Kim YS, et al. Comparative outcomes of open-wedge high tibial osteotomy with platelet-rich plasma alone or in combination with mesenchymal stem cell treatment: a prospective study. Arthroscopy. 2014;30(11):1453-1460.

56. Gan F, Tang C, Guo D, et al. The treatment of mesenchymal stem cell transplantation for knee osteoarthritis: a clinical observation study. Modem Diagn Treat. 2014;25(15):3512-3513. (Article in Chinese)

57. Orozco L, Munar A, Soler R, et al. Treatment of knee osteoarthritis with allogenic mesenchymal stem cells. 2014. https://www.clinicaltrials.gov. Identifier: NCT01586312.

58. Vangsness CT Jr, Farr J 2nd, Boyd J, et al. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study. J Bone Joint Surg Am. 2014;96(2):90-98.

59. Akgun I, Unlu MC, Erdal OA, et al. Matrix-induced autologous mesenchymal stem cell implantation versus matrix-induced autologous chondrocyte implantation in the treatment of chondral defects of the knee: a 2-year randomized study. Arch Orthop Trauma Surg. 2015;135(2):251-263.

60. Liang HS, Huang K, Li Lin, et al. Arthroscopic microfracture surgery combined with autologous bone marrow mesenchymal stem cells transplant in the treatment of knee cartilage defect. Chin J Mod Drug Appl. 2015;9(9):1-3. (Article in Chinese)

61. Lv XX, Huang C, Yin Z, et al. Effectiveness of autologous bone marrow mesenchymal stem cell transplant for knee osteoarthritis. Chin J Cell Stem Cell. 2015;5(2):28-32. (Article in Chinese)

62. Vega A, Martín-Ferrero MA, Del Canto F, et al. Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem Cells: A Randomized Controlled Trial. Transplantation. 2015;99(8):1681-1690.

63. Gupta PK, Chullikana A, Rengasamy M, et al. Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel®): preclinical and clinical trial in osteoarthritis of the knee joint. Arthritis Res Ther. 2016;18(1):301.

64. Lamo-Espinosa JM, Mora G, Blanco JF, et al. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II). J Transl Med. 2016;14(1):246.

65. Wang Y, Jin W, Liu H, et al. Curative effect of human umbilical cord mesenchymal stem cells by intra-articular injection for degenerative knee osteoarthritis. Chinese journal of reparative and reconstructive surgery. 2016;30(12):1472-1477. (Article in Chinese)

66. Yang Xiaobin, Jiang Feng, Zhang Fan, et al. Therapeutic effect of human umbilical cord-derived mesenchymal stem cells for severe knee osteoarthritis. Chinese Journal of Clinical Pharmacology and Therapeutics. 2017;22(3):305-311. (Article in Chinese)

67. Shapiro SA, Kazmerchak SE, Heckman MG, et al. A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis. Am J Sports Med. 2017;45(1):82-90.
68. Wang Y, Shimmin A, Ghosh P, et al. Safety, tolerability, clinical, and joint structural outcomes of a single intra-articular injection of allogeneic mesenchymal precursor cells in patients following anterior cruciate ligament reconstruction: a controlled double-blind randomised trial. Arthritis Res Ther. 2017;19(1):180.

69. Garay-Mendoza D, Villarreal-Martínez L, Garza-Bedolla A, et al. The effect of intra-articular injection of autologous bone marrow stem cells on pain and knee function in patients with osteoarthritis. Int J Rheum Dis. 2018;21(1):140-147.

70. Jo CH, Chai JW, Jeong EC, et al. Intra-articular Injection of Mesenchymal Stem Cells for the Treatment of Osteoarthritis of the Knee: A 2-Year Follow-up Study. Am J Sports Med. 2017;45(12):2774-2783.

71. Matas J, Orrego M, Espinoza F, et al. Allogeneic mesenchymal stromal cell (MSC) therapy for knee osteoarthritis (OA): a phase I/II randomized controlled trial. Cytoteraphy. 2017;19(5):24.

72. Kuah D, Sivell S, Longworth T, et al. Safety, tolerability and efficacy of intra-articular Progenza in knee osteoarthritis: a randomized double-blind placebo-controlled single ascending dose study. J Transl Med. 2018;16(1):49.

73. Ha CZ, Li W, Ren SD, et al. Effect of platelet rich plasma combined with mesenchymal stem cells in treatment of knee osteoarthritis. Chin J Joint Surg (Electronic Edition). 2018;12(5):644–652. (Article in Chinese)

74. Emadedin M, Labibzadeh N, Liastani MG, et al. Intra-articular implantation of autologous bone marrow–derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. Cytoteraphy. 2018;20(10):1238-1246.

75. Jones IA, Wilson M, Togashi R, et al. A randomized, controlled study to evaluate the efficacy of intra-articular, autologous adipose tissue injections for the treatment of mild-to-moderate knee osteoarthritis compared to hyaluronic acid: a study protocol. BMC Musculoskeletal Disord. 2018;19(1):383.

76. Lamo-Espinosa JM, Mora G, Blanco JF, et al. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II). J Transl Med. 2018;16(1):213.

77. Matas J, Orrego M, Amenabar D, et al. Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial. Stem Cells Transl Med. 2019;8(3):215-224.

78. Freitag J, Bates D, Wickham J, et al. Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial. Regen Med. 2019;14(3):213-230.

79. Hong Z, Chen J, Zhang S, et al. Intra-articular injection of autologous adipose-derived stromal vascular fractions for knee osteoarthritis: a double-blind randomized self-controlled trial. Int Orthop. 2019;43(5):1123-1134.
80. Khalifeh Soltani S, Forogh B, Ahmadbeigi N, et al. Safety and efficacy of allogenic placental mesenchymal stem cells for treating knee osteoarthritis: a pilot study. Cytotherapy. 2019;21(1):54-63.

81. Lee WS, Kim HJ, Kim KI, et al. Intra-Articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Phase IIb, Randomized, Placebo-Controlled Clinical Trial. Stem Cells Transl Med. 2019;8(6):504-511.

82. Lu L, Dai C, Zhang Z, et al. Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells: a prospective, randomized, double-blind, active-controlled, phase IIb clinical trial. Stem Cell Res Ther. 2019;10(1):143.

83. Shapiro SA, Arthurs JR, Heckman MG, et al. Quantitative T2 MRI Mapping and 12-Month Follow-up in a Randomized, Blinded, Placebo Controlled Trial of Bone Marrow Aspiration and Concentration for Osteoarthritis of the Knees. Cartilage. 2019;10(4):432-443.

84. Bastos R, Mathias M, Andrade R, et al. Intra-articular injection of culture-expanded mesenchymal stem cells with or without addition of platelet-rich plasma is effective in decreasing pain and symptoms in knee osteoarthritis: a controlled, double-blind clinical trial. Knee Surg Sports Traumatol Arthrosc. 2020;28(6):1989-1999.

85. Tran TDX, Wu CM, Dubey NK, et al. Time- and Kellgren-Lawrence Grade-Dependent Changes in Intra-Articularly Transplanted Stromal Vascular Fraction in Osteoarthritic Patients. Cells. 2019;8(4):308.

86. Khasru MR, Salek AM, Marzen T, et al. Peripheral blood derived stem cells in OA knee at low resource setting: a phase II RCT. Osteoarthritis Cartilage. 2019;27:512.

87. Garza JR, Campbell RE, Tjoumakaris FP, et al. Clinical Efficacy of Intra-articular Mesenchymal Stromal Cells for the Treatment of Knee Osteoarthritis: A Double-Blinded Prospective Randomized Controlled Clinical Trial. Am J Sports Med. 2020;48(3):588-598.

88. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

89. Yan P, Yao L, Li H, et al. The methodological quality of robotic surgical meta-analyses needed to be improved: a cross-sectional study. J Clin Epidemiol. 2019;109:20-29.

90. Siemens W, Schwarzer G, Rohe MS, et al. Methodological quality was critically low in 9/10 systematic reviews in advanced cancer patients-A methodological study. J Clin Epidemiol. 2021;136:84-95.

91. Impellizzeri FM, Jones DM, Griffin D, et al. Patient-reported outcome measures for hip-related pain: a review of the available evidence and a consensus statement from the International Hip-related Pain Research Network, Zurich 2018. Br J Sports Med. 2020;54(14):848-857.

92. Bicket AK, Le JT, Azuara-Blanco A, et al. Minimally Invasive Glaucoma Surgical Techniques for Open-Angle Glaucoma: An Overview of Cochrane Systematic Reviews and Network Meta-analysis. JAMA Ophthalmol. 2021:e212351.

93. Salvo EM, Ferko NC, Cash SB, et al. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment Pharmacol Ther. 2021;54(2):129-143.
94. Ge L, Tian JH, Li YN, et al. Association between prospective registration and overall reporting and methodological quality of systematic reviews: a meta-epidemiological study. J Clin Epidemiol. 2018;93:45-55.

95. Sideri S, Papageorgiou SN, Eliades T. Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality. J Clin Epidemiol. 2018;100:103-110.

96. Dwan K, Gamble C, Williamson PR, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review. PLoS One. 2013;8(7):e66844.

97. Winters M, Weir A. Grey matters; on the importance of publication bias in systematic reviews. Br J Sports Med. 2017;51(6):488-489.

98. Huang J, Qin X, Shen M, et al. The Effects of Tai Chi Exercise Among Adults With Chronic Heart Failure: An Overview of Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2021;8:589267.

99. Fortes PM, Marques SM, Viana KA, et al. The use of probiotics for improving lipid profiles in dyslipidemic individuals: an overview protocol. Syst Rev. 2018;7(1):165.

100. Wang X, Wang Y, Wei S, et al. An Overview of Systematic Reviews of Acupuncture for Infertile Women Undergoing in vitro Fertilization and Embryo Transfer. Front Public Health. 2021;9:651811.

101. Zhang J, Yu Q, Peng L, et al. Benefits and Safety of Chinese Herbal Medicine in Treating Psoriasis: An Overview of Systematic Reviews. Front Pharmacol. 2021;12:680172.

102. Pieper D, Puljak L, González-Lorenzo M, et al. Minor differences were found between AMSTAR 2 and ROBIS in the assessment of systematic reviews including both randomized and nonrandomized studies. J Clin Epidemiol. 2019;108:26-33.

103. Lorenz RC, Matthias K, Pieper D, et al. A psychometric study found AMSTAR 2 to be a valid and moderately reliable appraisal tool. J Clin Epidemiol. 2019;114:133-140.

104. Gates M, Gates A, Duarte G, et al. Quality and risk of bias appraisals of systematic reviews are inconsistent across reviewers and centers. J Clin Epidemiol. 2020;125:9-15.

105. Gates A, Gates M, Duarte G, et al. Evaluation of the reliability, usability, and applicability of AMSTAR, AMSTAR 2, and ROBIS: protocol for a descriptive analytic study. Syst Rev. 2018;7(1):85.

Tables

Due to technical limitations, tables 1 & 2 is only available as a download in the Supplemental Files section.

Figures
Figure 1

Flow diagram of study retrieval and selection
Figure 2

Methodology adherence of each item for included systematic reviews based on AMSTRA 2
Figure 3

Methodology adherence of overall confidence for included systematic reviews based on AMSTRA 2

| Risk of bias in the review | 100.00% |
|---------------------------|---------|
| 4. Synthesis and findings | 81.82%  |
|                           | 18.18%  |
| 3. Data collection and study appraisal | 50.00%  |
|                           | 50.00%  |
| 2. Identification and selection of studies | 86.36%  |
|                           | 4.55%   |
| 1. Study eligibility criteria | 63.64%  |
|                           | 31.82%  |
Figure 4

Risk of bias for included SRs/MAs based on ROBIS

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Tables.docx
- Additionalfile1.docx
- Additionalfile2.docx
- Additionalfile3.docx
- Additionalfile4.docx